Abstracts related to the use of Selenium and Chemotherapy in the treatment of Ovarian Cancer:
Gynecol Oncol. 2004 May;93(2):320-7.
Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.
Sieja K, Talerczyk M.
Department of Pharmacology, Pomeranian Academy of Medicine , Szczecin , Poland . firstname.lastname@example.org
OBJECTIVE: Our objective is to examine how selenium (Se) supplementation influences oxidative stress (malondialdehyde) and the glutathione peroxidase system in patients with ovarian cancer undergoing chemotherapy. MATERIAL: The study group included 31 patients with ovarian cancer undergoing chemotherapy receiving the drug Protecton Zellactiv (Smith Kline Beecham, Fink Naturarznei GmbH, Germany ), two capsules, four times daily (200 microg). RESULTS: Following the Se supplementation in a daily dose of 200 microg, the concentration of this microelement in serum (P < 0.05) and hair (P < 0.05) was significantly higher than in the control group. It has also been found that Se concentration in serum was significantly increased after 2 (P < 0.0000) and 3-months' (P < 0.0000) length of supplementation, as compared to the values after 1 month. In the hair of patients receiving this supplementation, an insignificantly higher concentration of this microelement was found after 2 (NS) and 3 months (NS) in comparison to the concentration after 1 month. The patients with ovarian cancer undergoing chemotherapy and receiving Se showed a significant increase in the activity of GSH-P(x) in erythrocytes after 2 months' (P < 0.0015) and 3 months' (P < 0.0038) supplementation. An increase of the concentration of malondialdehyde (MDA) following the administration of Se after 2 months (P < 0.0363) and 3 months (P < 0.0489) was found to be significant. The increase of MDA calculated into platelet count was found to be significant after 3 months (P 0.0477) of Se supplementation. Se administration for 3 months resulted in the significant increase of white blood cells (WBC) (P < 0.0001). After 2 and 3 months of Se administration, a significant decrease of hair loss (P < 0.0000; P < 0.0392, respectively ), flatulence (P < 0.0000; P< 0.0000), abdominal pain (P < 0.0006; P < 0.0202), weakness (P < 0.0001; P < 0.0000), malaise (P < 0.0017; P < 0.0000), loss of appetite (P < 0.0000; P < 0.0000) was stated. CONCLUSION: As a result of this clinical trial, we conclude that there are beneficial effects caused by ingesting selenium, as a supportive element in chemotherapy.
• Clinical Trial
• Controlled Clinical Trial
PMID: 15099940 [PubMed - indexed for MEDLINE]
Pharmazie. 2000 Dec;55(12):958-9.
Protective role of selenium against the toxicity of multi-drug chemotherapy in patients with ovarian cancer.
Department of Pharmacology and Toxicology and Department of Gynecological Surgery and Oncology of Adults and Children, Pomeranian Medical University , Szczecin , Poland .
• Clinical Trial
PMID: 11189880 [PubMed - indexed for MEDLINE]
Pharmazie. 1998 Jul;53(7):473-6.
Selenium (Se) deficiency in women with ovarian cancer undergoing chemotherapy and the influence of supplementation with this micro-element on biochemical parameters.
Department of Pharmacology, Pomeranian Academy of Medicine , Szczecin , Poland .
A clinical study was undertaken to evaluate the influence of a preparation containing selenium and vitamins with antioxidant properties (Protecton Zellaktiv from Smith Kline Naturarznei-Germany) on: (a) concentration of Se in serum and hair, (b) activity of glutathione peroxidase (GSH-Px), and (c) concentration of malondialdehyde (MDA) in serum, before and during supplementation. Women undergoing chemotherapy for ovarian cancer received selenium during three months at a daily dose of 200 micrograms. The results were compared with controls not receiving selenium supplementation. Administration of selenium significantly increased the serum and hair concentrations of selenium in the study group. After three months of supplementation the activity of GSH-Px was significantly higher in the study group. After one month of supplementation a difference in the concentration of MDA between the study and control groups was found. On the basis of the present results the administration of selenium in patients with ovarian cancer undergoing multi-drug chemotherapy is recommended.
• Clinical Trial
PMID: 9699224 [PubMed - indexed for MEDLINE]
Carcinogenesis. 1984 Jun;5(6):731-4.
Serum selenium in patients with ovarian cancer during and after therapy.
Sundstrom H, Yrjanheikki E, Kauppila A.
Serum concentrations of selenium were determined by atomic absorption spectrophotometry in 40 patients with ovarian cancer in association with and after surgical and cytostatic therapy. Patients with ovarian cancer had significantly (p less than 0.001) lower serum concentrations (mean +/- SE) of selenium (0.93 +/- 0.04 mumol/l) than age-, weight- and place of residence-matched control subjects (1.22 +/- 0.03 mumol/l). In clinical stage IV disease there was a lower serum level of selenium (0.82 +/- 0.07 mumol/l) than in clinical stages I and II combined (1.00 +/- 0.04 mumol/l). Serum selenium concentrations also showed a tendency to follow the outcome of the disease; an increase in patients with remission and a decrease in patients with progressive disease, probably because of nutritional reasons.
PMID: 6426813 [PubMed - indexed for MEDLINE]
Biol Trace Elem Res. 1997 Mar;56(3):331-41.
The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.
Hu YJ, Chen Y, Zhang YQ, Zhou MZ, Song XM, Zhang BZ, Luo L, Xu PM, Zhao YN, Zhao YB, Cheng G.
Department of Medical Oncology, Beijing Hospital , P.R., China .
The effect of selenium (Se) in reducing the toxicity of cisplatin in cancer patients was studied. Forty-one patients were randomized into group A (20 patients with Se administration in first cycle of chemotherapy as study cases and without Se in second cycle of chemotherapy as control) and group B (21 patients without Se in first cycle of chemotherapy and with Se in second cycle of chemotherapy). The 4000 micrograms per day of Se as Seleno-Kappacarrageenan were administered from 4 before to 4 d after chemotherapy for study cases. The serum Se increased from 70.4 +/- 22.86 to 157.04 +/- 60.23 ng/mL (P < 0.001) in patients received Se. The cisplatin dosage was iv administration in 60-80 mg/m2 on the first day. The results showed that the peripheral WBC counts on day 14 after initiation of chemotherapy in study cases was significantly higher than the controls (3.35 +/- 2.01 vs 2.31 +/- 1.38 [x10(9)L])/L, p < 0.05). On the other hand, the consumption of GCSF for the cases was significantly less than the controls (110.1 +/- 82.2 vs 723.6 +/- 192.6 IU, p < 0.05). The volumes of blood transfusion for the study group were also significantly less than the controls (0 vs 62 +/- 38 mL, p < 0.05). The nephrotoxicity of cisplatin was measured by urine enzymes (NAG, GGT, AAP, LAP, and ALP) were determined prior to and at 2, 24, 48, and 72 h after initiation of chemotherapy. The urine enzymes NAG, GGT, AAP, and ALP after chemotherapy for cases were significantly lower than the controls. No toxicity of Seleno-Kappacarrageenan was noted. The above results suggest that the Se can be used as an agent for reducing the nephrotoxicity and bone marrow suppression induced by cisplatin.
• Clinical Trial
• Randomized Controlled Trial
PMID: 9197929 [PubMed - indexed for MEDLINE]
Curr Pharm Des. 2001 Nov;7(16):1595-614.
A prevention strategy for circumventing drug resistance in cancer chemotherapy.
Frenkel GD, Caffrey PB.
Department of Biological Sciences, Rutgers University , Newark , NJ 07102 , USA . email@example.com
The development of drug resistance is considered to be a major cause for the failure of chemotherapy in a number of types of cancer, including ovarian, breast and lung. Most previous research has focused on approaches to reverse drug resistance once it has arisen, that is, on the use of agents which can make drug-resistant tumors more sensitive to chemotherapy. Unfortunately, this approach has thus far met with only limited clinical success. Because of the prevalence of drug resistance in cases of advanced cancer, there exists an urgent need to develop new approaches to dealing with this problem. We have hypothesized the feasibility of an alternative approach: the use of specific agents to prevent the development of resistance before it arises. Our initial studies to examine this hypothesis have focused on ovarian cancer. We have designed both in vitro and in vivo systems in which resistance develops rapidly after exposure of tumor cells or xenografts to melphalan or cisplatin. Using these systems we have shown that two selenium compounds, selenite and selenomethionine are able to prevent the induction of resistance. Furthermore, inclusion of selenite in a chemotherapeutic protocol can result in a significant enhancement of the efficacy of cisplatin in suppressing the growth of human ovarian tumor xenografts. These results have supported the idea that prevention may be a useful new approach to the problem of drug resistance in cancer chemotherapy.
PMID: 11562301 [PubMed - indexed for MEDLINE]